S3V Vascular Technologies Limited is an emerging Indian medical-device manufacturer specializing in cardiovascular and neurovascular intervention products. Founded in 2011 and headquartered in Mysuru, the company focuses on developing high-precision devices such as stents, PTCA balloon catheters, guidewires, microcatheters, and other lifesaving tools used in minimally invasive procedures. Its mission centers on making advanced medical technology affordable and accessible within India, a country that relies heavily on imported devices. By investing in R&D and maintaining stringent global-standard manufacturing practices, S3V has positioned itself as a strong domestic contender in a highly specialized healthcare segment.
In recent years, S3V has gained significant attention for developing India’s first fully indigenized suite of mechanical thrombectomy devices used in the treatment of acute ischemic stroke. These devices—traditionally imported at very high costs—play a critical role in restoring blood flow to the brain during a stroke. S3V’s innovation aims to bring down treatment costs dramatically, potentially allowing more hospitals and patients to access advanced stroke-care solutions. The company has also attracted notable investments through funding rounds designed to support expansion of its manufacturing capabilities. With plans for integrated facilities covering both cardiac and neurovascular product lines, S3V is gearing up to enhance production scale, strengthen quality control, and improve its competitiveness in both domestic and international markets.
As an unlisted company, S3V Vascular Technologies Limited offers long-term growth potential but also carries typical risks associated with unlisted equities. Its shares are not traded on public exchanges, making price discovery and liquidity more limited for investors. However, the company’s strong technological focus, rising demand for indigenous medical devices, and strategic push toward affordability and self-reliance position it favorably within India’s rapidly expanding medical-technology landscape. For investors and industry observers, S3V represents a blend of innovation, unmet market need, and growth momentum—though careful due diligence is essential, given the specialized nature of the sector and the limited public financial disclosure inherent to unlisted firms.
Q:1 How do I confirm my booking for S3V Vascular Technologies Limited unlisted shares?Answer: You can confirm your booking by reaching out to us and specifying the trading price for the shares you wish to purchase.
Q:2 What documents do I need to provide for the purchase of S3V Vascular Technologies Limited shares?Answer: You need to provide your client master report, PAN Card, and a Cancelled Cheque if you are not transferring funds from the bank account as mentioned in the CMR Copy.These documents are required for KYC compliance as per SEBI regulations.
Q:3 How will I receive the bank details for the fund transfer?
Answer: Once you confirm your booking, we will provide you with the necessary bank details for the fund transfer.
Q:4 What payment methods are accepted for purchasing S3V Vascular Technologies Limited shares?Answer: Payments can be made via RTGS, NEFT, IMPS, or cheque transfer.Please note that cash deposits are not accepted.
Q:5 Can I make the payment from a different bank account than the one mentioned in the CMR Copy?Answer: No, the payment must be made from the same bank account where the shares are to be credited.
Q:6 Is there a specific method I should use for fund transfers?Answer: You should use RTGS, NEFT, or IMPS for fund transfers.Cheque transfers are also accepted, but cash deposits are not allowed.
Q:7 What happens if I don't have a client master report?Answer: If you do not have a client master report, please ask your broker to provide one, as it is necessary for the KYC documentation.
Q:8 What is the purpose of providing a cancelled cheque?Answer: A cancelled cheque is required to verify the bank account from which the funds will be transferred and to ensure that the shares are credited to the correct account.